Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs

Neuroscience

Volumn 361, Issue , 2017, Pages 43-57

  Lévesque, Catherine ^a   Hernandez, Giovanni ^a   Mahmoudi, Souha ^a   Calon, Frédéric ^b   Gasparini, Fabrizio ^c   Gomez mancilla, Baltazar ^c,d   Blanchet, Pierre J ^a   Lévesque, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

clozapine; dopamine; glutamate; haloperidol; monkey; serotonin

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR 5; GLUTAMIC ACID; HALOPERIDOL DECANOATE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; HALOPERIDOL;

AMINERGIC NEUROTRANSMISSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EXPOSURE; FEMALE; GLUTAMATERGIC NEUROTRANSMISSION; IN SITU HYBRIDIZATION; NEUROCHEMISTRY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRESYNAPTIC NERVE; PRIMATE; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; RECEPTOR BINDING; SAPAJUS APELLA; TARDIVE DYSKINESIA; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; DYSKINESIA; HAPLORHINI; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HAPLORHINI; PUTAMEN; TARDIVE DYSKINESIA;

EID: 85027895221     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2017.07.068     Document Type: Article

References (80)

1. 2 receptor binding. J Neural Transm Gen Sect 79 (1990), 215–226.
2. Andreassen, O.A., Jorgensen, H.A., Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog Neurobiol 61 (2000), 525–541.
3. Aparicio-Legarza, M.I., Davis, B., Hutson, P.H., Reynolds, G.P., Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett 241 (1998), 143–146.
4. Blanchet, P.J., Parent, M.T., Rompré, P.H., Lévesque, D., Relevance of animal models to human tardive dyskinesia. Behav Brain Funct, 8, 2012, 12.
5. 125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester. Mol Pharmacol 47 (1995), 779–786.
6. Burnet, P.W., Chen, C.P., McGowan, S., Franklin, M., Harrison, P.J., The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73 (1996), 531–540.
7. Calon, F., Morissette, M., Ghribi, O., Goulet, M., Grondin, R., Blanchet, P.J., Bédard, P.J., Di Paolo, T., Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002), 127–138.
8. Calon, F., Rajput, A.H., Hornykiewicz, O., Bédard, P.J., Di Paolo, T., Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14 (2003), 404–416.
9. Cenci, M.A., Konradi, C., Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183 (2010), 209–233.
10. Creed, M.C., Nobrega, J.N., Neurobiological basis of dyskinetic effects induced by antipsychotics: the contribution of animal models. Curr Med Chem 20 (2013), 389–396.
11. 2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 219 (2011), 273–279.
12. 2A receptors: emphasis on the rat frontal cortex. Neuroscience 83 (1998), 829–836.
13. Dean, B., Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. Postgrad Med J 78 (2002), 142–148.
14. 2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 85 (2003), 1–13.
15. Eastwood, S.L., Heffernan, J., Harrison, P.J., Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Mol Psychiatry 2 (1997), 322–329.
16. Egan, M.F., Hurd, Y., Ferguson, J., Bachus, S.E., Hamid, E.H., Hyde, T.M., Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology 127 (1996), 337–345.
17. Fusar-Poli, P., Meyer-Lindenberg, A., Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull 39 (2013), 22–32.
18. 2 serotonin receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 367 (2003), 615–620.
19. Gardoni, F., Frasca, A., Zianni, E., Riva, M.A., Di Luca, M., Fumagalli, F., Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum. Eur Neuropsychopharmacol 18 (2008), 531–534.
20. 2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 259 (1991), 409–413.
21. 2A receptors by agonists and antagonists. Brain Res Bull 56 (2001), 441–451.
22. Grégoire, L., Morin, N., Ouattara, B., Gasparini, F., Bilbe, G., Johns, D., Vranesic, I., Sahasranaman, S., Gomez-Mancilla, B., Di Paolo, T., The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17 (2011), 270–276.
23. Guay, D.R., Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 8 (2010), 331–373.
24. Gupta, D.S., McCullumsmith, G.E., Beneyto, M., Haroutunian, V., Davis, K.L., Meador-Woodruff, J.H., Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57 (2005), 123–131.
25. Hamid, E.H., Hyde, T.M., Baca, S.M., Egan, M.F., Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia. Brain Res 796 (1998), 291–295.
26. Hintermann, S., Vranesic, I., Allgeier, H., Brulisauer, A., Hoyer, D., Lemaire, M., Moenius, T., Urwyler, S., Whitebread, S., Gasparini, F., Auberson, Y.P., ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg Med Chem 15 (2007), 903–914.
27. 2A and 2C receptor mRNA expression in the rat brain. Neurosci Res 59 (2007), 314–321.
28. Konitsiotis, S., Tsironis, C., Kiortsis, D.N., Evangelou, A., Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias. Psychopharmacology 185 (2006), 369–377.
29. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13 (1995), 139–150.
30. 2A receptors in the rat brain. J Neural Transm 107 (2000), 295–302.
31. 2C receptors and the motor control of oral activity. Curr Neuropharmacol 11 (2013), 160–170.
32. Lerner, P.P., Miodownik, C., Lerner, V., Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. Psychiatry Clin Neurosci 69 (2015), 321–334.
33. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lassig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
34. 2-serotoninergic sites in the primate cerebral cortex. Schizophrenia Res, 15, 1995, 158.
35. Lidow, M.S., Song, Z.M., Castner, S.A., Allen, P.B., Greengard, P., Goldman-Rakic, P.S., Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry 49 (2001), 1–12.
36. Lieberman, J.A., Bymaster, F.P., Meltzer, H.Y., Deutch, A.Y., Duncan, G.E., Marx, C.E., Aprille, J.R., Dwyer, D.S., Li, X.M., Mahadik, S.P., Duman, R.S., Porter, J.H., Modica-Napolitano, J.S., Newton, S.S., Csernansky, J.G., Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60 (2008), 358–403.
37. Lister, J., Nobrega, J.N., Fletcher, P.J., Remington, G., Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology 231 (2014), 2237–2249.
38. 3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 42 (2001), 12–26.
39. Mahmoudi, S., Blanchet, P.J., Lévesque, D., Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia. Eur J Neurosci 38 (2013), 2192–2198.
40. 2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord 29 (2014), 1125–1133.
41. Matosin, N., Frank, E., Deng, C., Huang, X.F., Newell, K.A., Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr Res 146 (2013), 170–176.
42. 2 receptor density in rat cerebral cortex. Life Sci 45 (1989), 1397–1406.
43. McCullumsmith, R.E., Stincic, T.L., Agrawal, S.M., Meador-Woodruff, J.H., Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat. Eur J Pharmacol 477 (2003), 101–112.
44. Meador-Woodruff, J.H., Hogg, A.J. Jr., Smith, R.E., Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55 (2001), 631–640.
45. Meltzer, H.Y., Update on typical and atypical antipsychotic drugs. Annu Rev Med 64 (2013), 393–406.
46. Millan, M.J., N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179 (2005), 30–53.
47. Morin, N., Grégoire, L., Gomez-Mancilla, B., Gasparini, F., Di Paolo, T., Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58 (2010), 981–986.
48. Morin, N., Morissette, M., Grégoire, L., Gomez-Mancilla, B., Gasparini, F., Di Paolo, T., Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 73 (2013), 216–231.
49. Morissette, M., Dridi, M., Calon, F., Tahar, A.H., Meltzer, L.T., Bédard, P.J., Di Paolo, T., Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin. Mov Disord 21 (2006), 9–17.
50. Noga, J.T., Hyde, T.M., Herman, M.M., Spurney, C.F., Bigelow, L.B., Weinberger, D.R., Kleinman, J.E., Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 27 (1997), 168–176.
51. Ossowska, K., Pietraszek, M., Wardas, J., Nowak, G., Wolfarth, S., Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 359 (1999), 280–287.
52. Ouattara, B., Gasparini, F., Morissette, M., Grégoire, L., Samadi, P., Gomez-Mancilla, B., Di Paolo, T., Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113 (2010), 715–724.
53. Ouattara, B., Grégoire, L., Morissette, M., Gasparini, F., Vranesic, I., Bilbe, G., Johns, D.R., Rajput, A., Hornykiewicz, O., Rajput, A.H., Gomez-Mancilla, B., Di Paolo, T., Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 32 (2011), 1286–1295.
54. Pappa, S., Tsouli, S., Apostolou, G., Mavreas, V., Konitsiotis, S., Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33 (2010), 271–275.
55. Parent, A., Hazrati, L.-N., Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20 (1995), 91–127.
56. Paxinos, G., The rherus monkey brain in stereotaxic coordinates. 2009, Academic Press, Boston.
57. Purves-Tyson, T.D., Owens, S.J., Rothmond, D.A., Halliday, G.M., Double, K.L., Stevens, J., McCrossin, T., Shannon Weickert, C., Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. Transl Psychiatry, 7, 2017, e1003.
58. Rana, A.Q., Chaudry, Z.M., Blanchet, P.J., New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 7 (2013), 1329–1340.
59. Reader, T.A., Ase, A.R., Huang, N., Hebert, C., van Gelder, N.M., Neuroleptics and dopamine transporters. Neurochem Res 23 (1998), 73–80.
60. Rehavi, M., Goldin, M., Roz, N., Weizman, A., Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Brain Res Mol Brain Res 57 (1998), 31–37.
61. Rehavi, M., Roz, N., Weizman, A., Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2. Eur Neuropsychopharmacol 12 (2002), 261–268.
62. 2A receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 33 (2011), 1823–1831.
63. Rivest, R., Falardeau, P., Di Paolo, T., Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692 (1995), 269–272.
64. Rodriguez-Oroz, M.C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., Obeso, J.A., Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8 (2009), 1128–1139.
65. Ryu, S., Yoo, J.H., Kim, J.H., Choi, J.S., Baek, J.H., Ha, K., Kwon, J.S., Hong, K.S., Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. J Clin Psychopharmacol 35 (2015), 13–21.
66. Samadi, P., Grégoire, L., Morissette, M., Calon, F., Hadj Tahar, A., Dridi, M., Bélanger, N., Meltzer, L.T., Bédard, P.J., Di Paolo, T., MGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 29 (2008), 1040–1051.
67. 2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy. Neuropharmacology 60 (2011), 642–652.
68. Schmitt, A., Zink, M., Muller, B., May, B., Herb, A., Jatzko, A., Braus, D.F., Henn, F.A., Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 28 (2003), 235–241.
69. Schoonover, K.E., McCollum, L.A., Roberts, R.C., Protein markers of neurotransmitter synthesis and release in postmortem schizophrenia substantia nigra. Neuropsychopharmacology 42 (2017), 540–550.
70. Seeman, P., Tinazzi, M., Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 44 (2013), 178–183.
71. Sgambato-Faure, V., Cenci, M.A., Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 96 (2012), 69–86.
72. Spurney, C.F., Baca, S.M., Murray, A.M., Jaskiw, G.E., Kleinman, J.E., Hyde, T.M., Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34 (1999), 266–276.
73. Tamminga, C.A., Dale, J.M., Goodman, L., Kaneda, H., Kaneda, N., Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102 (1990), 474–478.
74. Tamminga, C.A., Thaker, G.K., Moran, M., Kakigi, T., Gao, X.M., Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55:Suppl B (1994), 102–106.
75. 2 receptor occupancy?. Neurosci Biobehav Rev 26 (2002), 361–380.
76. 2C receptors and their atypical regulation properties. Life Sci 72 (2003), 2429–2449.
77. 2) receptors in the rat brain. Brain Res 487 (1989), 288–298.
78. Yoder, K.K., Hutchins, G.D., Morris, E.D., Brashear, A., Wang, C., Shekhar, A., Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71 (2004), 371–375.
79. Zai, C.C., Tiwari, A.K., Mazzoco, M., de Luca, V., Muller, D.J., Shaikh, S.A., Lohoff, F.W., Freeman, N., Voineskos, A.N., Potkin, S.G., Lieberman, J.A., Meltzer, H.Y., Remington, G., Kennedy, J.L., Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 47 (2013), 1760–1765.
80. Zhang, G., Terry, A.V. Jr., Bartlett, M.G., Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 858 (2007), 276–281.